

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07H 21/00, 21/04	A1	(11) International Publication Number: WO 99/64433 (43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/US99/13121 (22) International Filing Date: 10 June 1999 (10.06.99) (30) Priority Data: 09/095,811 11 June 1998 (11.06.98) US (71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ELEUTERI, Alessandra [IT/US]; 1269 Eolus Avenue, Encinitas, CA 92024 (US). CAPALDI, Daniel, C. [GB/US]; Apartment #2125, 3855 Nobel Drive, San Diego, CA 92122 (US). RAVIKUMAR, Vasulinga, T. [IN/US]; 6606 Vireo Court, Carlsbad, CA 92009 (US). (74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: METHOD OF PREPARING PHOSPHORAMIDITES		
(57) Abstract		
Improved methods for preparation of phosphoramidite compounds are disclosed. The phosphoramidites are useful, for example, for the preparation of oligonucleotides by solid state oligonucleotide synthetic regimes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHOD OF PREPARING PHOSPHORAMIDITES

FIELD OF THE INVENTION

This invention is directed to methods for the preparation of phosphoramidite compounds that are useful, for example, in the solid phase synthesis of oligonucleotides. The oligonucleotides are useful as diagnostic reagents, research reagents and therapeutics agents.

BACKGROUND OF THE INVENTION

10 It is well known proteins are significantly involved in many of the bodily states in multicellular organisms, including most disease states. Such proteins, either acting directly or through their enzymatic or other functions, contribute in major proportion to many diseases and regulatory functions in animals and man. For disease states, classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate their disease-causing or disease-potentiating functions. In newer therapeutic approaches, modulation of the production of such proteins is desired. By interfering with the production of proteins, the maximum therapeutic effect might be obtained with minimal side effects. It is the general object of such therapeutic approaches to interfere with or otherwise modulate gene expression which would lead to undesired protein formation.

25 One method for inhibiting specific gene expression

is with the use of oligonucleotides, especially oligonucleotides which are complementary to a specific target messenger RNA (mRNA) sequence.

Transcription factors interact with double-
5 stranded DNA during regulation of transcription. Oligonucleotides can serve as competitive inhibitors of transcription factors to modulate the action of transcription factors. Several recent reports describe such interactions (see Bielinska, A., et. al., *Science*, 1990,
10 250, 997-1000; and Wu, H., et. al., *Gene*, 1990, 89, 203-209).

In addition to functioning as both indirect and direct regulators of proteins, oligonucleotides have also found use in diagnostic tests. Such diagnostic tests can be
15 performed using biological fluids, tissues, intact cells or isolated cellular components. As with gene expression inhibition, diagnostic applications utilize the ability of oligonucleotides to hybridize with a complementary strand of nucleic acid. Hybridization is the sequence specific
20 hydrogen bonding of oligonucleotides, via Watson-Crick and/or Hoogsteen base pairs, to RNA or DNA. The bases of such base pairs are said to be complementary to one another.

Oligonucleotides are also widely used as research reagents. They are useful for understanding the function of
25 many other biological molecules as well as in the preparation of other biological molecules. For example, the use of oligonucleotides as primers in polymerase chain reactions (PCR) has given rise to an expanding commercial industry. PCR has become a mainstay of commercial and
30 research laboratories, and applications of PCR have multiplied. For example, PCR technology is used in the fields of forensics, paleontology, evolutionary studies and genetic counseling. Commercialization has led to the development of kits which assist non-molecular biology-
35 trained personnel in applying PCR. Oligonucleotides, both

natural and synthetic, are employed as primers in PCR technology.

Laboratory uses of oligonucleotides are described generally in laboratory manuals such as *Molecular Cloning, A Laboratory Manual*, Second Ed., J. Sambrook, et al., Eds., Cold Spring Harbor Laboratory Press, 1989; and *Current Protocols In Molecular Biology*, F. M. Ausubel, et al., Eds., Current Publications, 1993. Such uses include Synthetic Oligonucleotide Probes, Screening Expression Libraries with Antibodies and Oligonucleotides, DNA Sequencing, In Vitro Amplification of DNA by the Polymerase Chain Reaction and Site-directed Mutagenesis of Cloned DNA (see Book 2 of *Molecular Cloning, A Laboratory Manual*, *ibid.*) and DNA-Protein Interactions and The Polymerase Chain Reaction (see Vol. 2 of *Current Protocols In Molecular Biology*, *ibid.*).

Oligonucleotides can be custom-synthesized for a desired use. Thus a number of chemical modifications have been introduced into oligonucleotides to increase their usefulness in diagnostics, as research reagents and as therapeutic entities. Such modifications include those designed to increase binding to a target strand (i.e. increase their melting temperatures, (T_m)); to assist in identification of the oligonucleotide or an oligonucleotide-target complex; to increase cell penetration; to stabilize against nucleases and other enzymes that degrade or interfere with the structure or activity of the oligonucleotides; to provide a mode of disruption (terminating event) once sequence-specifically bound to a target; and to improve the pharmacokinetic properties of the oligonucleotides.

Thus, it is of increasing value to prepare oligonucleotides and other phosphorus-linked oligomers for use in basic research or for diagnostic or therapeutic applications. Consequently, and in view of the considerable

expense and time required for synthesis of specific oligonucleotides, there has been a longstanding effort to develop successful methodologies for the preparation of specific oligonucleotides with increased efficiency and
5 product purity.

Synthesis of oligonucleotides can be accomplished using both solution phase and solid phase methods. Oligonucleotide synthesis via solution phase in turn can be accomplished with several coupling mechanisms. However,
10 solution phase chemistry requires purification after each internucleotide coupling, which is labor intensive and time consuming.

The current method of choice for the preparation of naturally occurring oligonucleotides, as well as modified
15 oligonucleotides such as phosphorothioate and phosphorodithioate oligonucleotides, is via solid-phase synthesis wherein an oligonucleotide is prepared on a polymer support (a solid support) such as controlled pore glass (CPG); oxalyl-controlled pore glass (see, e.g., Alul, et al.,
20 *Nucleic Acids Research* 1991, 19, 1527); TENTAGEL Support, (see, e.g., Wright, et al., *Tetrahedron Letters* 1993, 34, 3373); or POROS, a polystyrene resin available from Perceptive Biosystems. Solid-phase synthesis relies on sequential addition of nucleotides to one end of a growing
25 oligonucleotide chain. Typically, a first nucleoside (having protecting groups on any exocyclic amine functionalities present) is attached to an appropriate glass bead support and activated phosphite compounds (typically nucleotide phosphoramidites, also bearing appropriate
30 protecting groups) are added stepwise to elongate the growing oligonucleotide. The nucleotide phosphoramidites are reacted with the growing oligonucleotide using "fluidized bed" technology to mix the reagents. The known silica supports suitable for anchoring the oligonucleotide
35 are very fragile and thus cannot be exposed to aggressive

mixing.

Additional methods for solid-phase synthesis may be found in Caruthers U.S. Patents Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and 5,132,418; 5 and Koster U.S. Patents Nos. 4,725,677 and Re. 34,069.

Phosphoramidites typically have been prepared by one of three routes. In the first, a suitably protected nucleobase is reacted with a protected bis-dialkylamino phosphite compound in the presence of 1H-tetrazole or a 10 tetrazole salt. See Nielsen, J. et al., *Nucleic Acids Res.* 1986, 14, 7391; Nielsen, J. et al., *J. Chem. Res. (S)* 1986, 26; Hamamoto, S. et al., *Chem. Lett.* 1986, 1401; and Nielsen, J. et al., *Nucleic Acids Res.* 1987, 15, 3626. This method is disadvantageous because, *inter alia*, tetrazole is 15 a health hazard, and poses disposal problems due to its explosive nature.

A second method for the preparation of phosphoramidites involves reacting the 3'-hydroxyl of a nucleoside with a protected dialkylamino chloro 20 phosphitylating reagent. See Hering, G. et al., *Nucleosides Nucleotides* 1985, 4, 169; and Ugi, I. et al., *J. Chem. Soc. Chem. Commun.* 1997, 877. This method also is disadvantageous because of the explosive nature of the phosphitylating reagent.

25 A third method for the synthesis of phosphoramidites involves reacting the 3'-hydroxyl of a nucleoside with a dialkylamino dichloro compound, followed by displacement of chlorine with addition of a protecting group. Tanaka, T. et al., *Tetrahedron Lett.* 1986, 27, 199.

30 Phosphordiamidites also can be prepared, for example, by the condensation of a bis(dialkylamino) chlorophosphine with a 5'-protected nucleoside according to the procedure of Uznanski et al., *Tetrahedron Letters* 1989 30 (5) 543-546.

35 Potential applications of oligonucleotides as


drugs have created a new challenges in the large-scale synthesis of these compounds. Thus, there remains a need for improved methods of preparing phosphoramidite synthons. The present invention is directed to this, as well as other, 5 important ends.

SUMMARY OF THE INVENTION

The present invention provides novel methods for the preparation of mononucleoside phosphoramidites or oligonucleotide phosphoramidites comprising the steps of:


10 reacting a mononucleoside or oligonucleotide having a free 3'-hydroxyl with a diaminohalophosphine; and contacting the product of the reaction with a reagent of formula R_4-OH , where R_4 is a phosphorus protecting group, under conditions of time and temperature sufficient 15 to form the mononucleoside or oligonucleoside phosphoramidite.

In preferred embodiments, methods are provided for the preparation of phosphoramidite compounds of Formula I:




wherein:

- R_1 is a hydroxyl protecting group;
 B is a nucleobase;
 M is an internucleotide linkage;
5 q is 0 to about 100;
 Z is H, OH, F, or a group of formula $R_7-(R_8)_n$;
 R_7 is C_3-C_{20} alkyl, C_4-C_{20} alkenyl, C_2-C_{20} alkynyl, C_1-C_{20} alkoxy, C_2-C_{20} alkenyloxy, or C_2-C_{20} alkynyloxy;
 R_8 is hydrogen, amino, halogen, hydroxyl,
10 thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide,
15 disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleo-
20 tides;
 n is from 0 to about 10;
 R_3 is a group of formula $-N(R_5)(R_6)$;
 R_5 and R_6 are independently alkyl having from one to four carbon atoms, or R_5 and R_6 taken together with
25 the nitrogen atom to which they are attached form an aliphatic or aromatic five or six membered ring;
 R_4 is a phosphorus protecting group;
comprising:
providing a compound of Formula II:




II

reacting the compound of Formula II with a
 5 diaminohalophosphine of Formula III:



III

wherein X is halogen; and R₂ is a group of
 formula -N(R₅)(R₆);
 10 to produce a phosphordiamidite of Formula IV:



IV

and

contacting the phosphordiamidite with a reagent of Formula

5 R_4 -OH to produce the phosphoramidite of Formula I.

In some preferred embodiments, q is 0.

In some preferred embodiments, R_1 is trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, 9-phenylxanthine-9-yl (Pixyl) or
 10 9-(*p*-methoxyphenyl)xanthine-9-yl (MOX), with trityl, monomethoxy trityl and dimethoxytrityl being more preferred.

In further preferred embodiments, R_5 and R_6 are each alkyl, with isopropyl being more preferred.

In some preferred embodiments, Z is H, OH, F, or a
 15 group of formula $R_7-(R_8)_n$ where R_7 is C_1 - C_{20} alkoxy, C_2 - C_{20} alkenyloxy, or C_2 - C_{20} alkynyloxy, R_8 is hydrogen or O-alkyl, and n is 1.

In further preferred embodiments, R_4 is β -cyanoethyl, diphenylsilylethyl, δ -cyanobutenyl, cyano *p*-
 20 xylyl (CPX), *N*-methyl-*N*-trifluoroacetyl ethyl (META), acetoxy phenoxy ethyl (APE), or butene-4-yl, with β -

cyanoethyl, diphenylsilylethyl, δ -cyanobutenyl or cyano *p*-xylyl being more preferred.

In some preferred embodiments, X is chlorine.

In further preferred embodiments, each R₅ and R₆ is
5 alkyl, with isopropyl being preferred.

In more preferred embodiments, R₄ is β -cyanoethyl, diphenylsilylethyl, δ -cyanobutenyl acetoxy phenoxy ethyl (APE), or cyano *p*-xylyl; and each R₅ and R₆ is alkyl, with
isopropyl being preferred.

10 In further preferred embodiments, the nucleoside is reacted with the diaminohalophosphine in the presence of pyridine, triethylamine or a mixture thereof.

In still further preferred embodiments, the nucleoside phosphordiamidite is contacted with the reagent
15 of formula R₄-OH in the presence of triethylamine, pyridine or a mixture thereof.

In even further preferred embodiments, the nucleoside phosphordiamidite is contacted with the reagent of formula R₄-OH without addition of further reagents.


20 DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention provides novel methods for the preparation of mononucleoside phosphoramidites or oligonucleotide phosphoramidites. In some preferred
embodiments, the methods of the invention comprise the steps
25 of:

reacting a mononucleoside or oligonucleotide having a free 3'-hydroxyl with a diaminohalophosphine; and
contacting the product of the reaction with a reagent of formula R₄-OH, where R₄ is a phosphorus protecting
30 group, under conditions of time and temperature sufficient to form the mononucleoside or oligonucleoside phosphoramidite.

In more preferred embodiments, methods are provided for the preparation of phosphoramidite compounds of

Formula I:



wherein:

- 5 R_1 is a hydroxyl protecting group;
 B is a nucleobase;
 M is an internucleotide linkage;
 q is 0 to about 100;
 Z is H, OH, F, or a group of formula $R_7 - (R_8)_n$;
 10 R_7 is C_3 - C_{20} alkyl, C_4 - C_{20} alkenyl, C_2 - C_{20}
 alkynyl, C_1 - C_{20} alkoxy, C_2 - C_{20} alkenyloxy, or C_2 - C_{20} alkynyloxy;
 R_8 is hydrogen, amino, halogen, hydroxyl,
 thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluor-
 omethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-
 15 dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-
 aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino,
 hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide,
 disulfide, silyl, aryl, heterocycle, carbocycle, inter-
 calator, reporter molecule, conjugate, polyamine, polyamide,
 20 polyalkylene glycol, polyether, a group that enhances the
 pharmacodynamic properties of oligonucleotides, or a group

- 12 -

that enhances the pharmacokinetic properties of oligonucleotides;

n is from 0 to about 10;


R₃ is a group of formula -N(R₅)(R₆);

- 5 R₅ and R₆ are independently alkyl having from one to four carbon atoms, or R₅ and R₆ taken together with the nitrogen atom to which they are attached form an aliphatic or aromatic five or six membered ring;

R₄ is a phosphorus protecting group;

- 10 comprising:


providing a compound of Formula II:



II

- 15 reacting the compound of Formula II with a diaminoalophosphine of Formula III:


- 13 -



III

wherein X is halogen; and R₂ is a group of formula -N(R₅)(R₆);

5 to produce a phosphordiamidite of Formula IV:



IV

and

contacting the phosphordiamidite with a reagent of Formula
10 R₄-OH to produce the phosphoramidite of Formula I.

The present invention provides methods for the preparation of phosphoramidite compounds that are comparable in efficiency to the methods currently used for production of phosphoramidites, yet do not require the preparation or
15 use of phosphitylating reagents, such as NC-CH₂-CH₂-O-P[N(*i*-pr)₂]₂, (cyanoethyl-bisdiisopropylamino phosphordiamidite) or the use of tetrazole activators, both of which are

potentially explosive. Thus, the methods of the present invention are advantageous in that they afford greater safety than currently used methodologies for phosphoramidite production.

5 In accordance with the methods of the present invention, a mononucleoside or an oligonucleotide having a free 3'-hydroxyl is reacted with a diaminoalophosphine to produce an intermediate phosphordiamidite, and an amine hydrochloride byproduct. In some especially preferred
10 embodiments of the methods of the invention, the reaction is performed in acetonitrile solvent. Thus, the present invention provides the additional advantage of not requiring the use of halogenated organic solvents, such as dichloromethane, which are disadvantageous because of their
15 toxicity and problems associated with their disposal. It will be appreciated, however, that while use of acetonitrile affords the additional advantages described above, use of halogenated organic solvents, if desired, is also suitable in the methods of the invention.

20 The mononucleoside or oligonucleotide having a free 3'-hydroxyl is preferably reacted with the diaminoalophosphine in the presence of a base, for example pyridine, triethylamine or a mixture thereof. Hunigs base and diisopropylethylamine are further examples of bases that
25 are amenable to this reaction. A preferred base for this reaction is triethylamine.

In accordance with preferred embodiments of the methods of the invention, the intermediate phosphordiamidite is reacted with an alcohol of formula $R_4\text{-OH}$, where R_4 is a
30 phosphorus protecting group, to yield the phosphoramidite product. While not wishing to be bound by a specific theory, it is believed that the reaction of the mononucleoside or an oligonucleotide having a free 3'-hydroxyl with a diaminoalophosphine produces an amine
35 hydrochloride byproduct, which serves as an activator in the subsequent reaction between the phosphordiamidite and the

alcohol of formula R_4 -OH.

Preferably, the phosphordiamidite is contacted with the alcohol of formula R_4 -OH in the same solvent as is used in the reaction between the mononucleoside or
5 oligonucleotide and the diaminohalophosphine, and also in the presence of the same base, for example, pyridine, triethylamine, or a mixture thereof.

As used herein, the term "contacting" means directly or indirectly causing at least two moieties to come
10 into physical association with each other. Contacting thus includes physical acts such as placing the moieties together in a container, or placing together in solution.

In some preferred embodiments, the reaction of the compound of Formula II and the diaminohalophosphine of
15 Formula III, and the contacting of the intermediate phosphordiamidite of Formula IV with the reagent of Formula R_4 -OH is advantageously performed in "one-pot" i.e., in a single container, thus affording significant benefits of time and expense. The methods of the present invention are
20 therefore especially beneficial in the large-scale production of phosphoramidites. Preferably, the methods of the invention are advantageously performed at ambient pressure and temperature.

The methods of the present invention are useful
25 for the preparation of, *inter alia*, nucleoside phosphoramidites that can bear protecting groups. Protecting groups are used in the oligonucleotide synthetic methods of the invention for protection of several different types of functionality. In general, protecting groups
30 render chemical functionality inert to specific reaction conditions and can be appended to and removed from such functionality in a molecule without substantially damaging the remainder of the molecule. Representative protecting groups are discussed in Greene and Wuts, *Protective Groups*
35 in *Organic Synthesis*, Chapter 7, 2d ed, John Wiley & Sons,

New York, 1991.

In some preferred embodiments of the invention R_1 is a hydroxyl protecting group. A wide variety of hydroxyl protecting groups can be employed in the methods of the invention. Suitable hydroxyl protecting groups include, for example, groups that are useful for protecting 5'-hydroxyl groups during, for example, solid state oligonucleotide synthetic regimes. Preferably, such a 5'-hydroxyl protecting group is stable under basic conditions but can be removed under acidic conditions. Representative hydroxyl protecting groups are disclosed by Beaucage, et al., *Tetrahedron* 1992, 48, 2223-2311, and also in Greene and Wuts, *supra*, at Chapter 2. Preferred protecting groups used for R_1 include trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, 9-phenylxanthine-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthine-9-yl (MOX).

Removal of hydroxyl protecting groups can be effected by techniques well known in the art to form the free hydroxyl. For example, dimethoxytrityl protecting groups can be removed by protic acids such as formic acid, dichloroacetic acid, trichloroacetic acid, p-toluene sulphonic acid or with Lewis acids such as for example zinc bromide. See for example, Greene and Wuts, *supra*.

In preferred embodiments of the methods of the invention, a 5'-protected mononucleoside or oligomeric compound having a free 3'-hydroxyl is reacted with a diaminoalophosphine to produce an intermediate nucleoside phosphordiamidite. The diaminoalophosphine preferably has the formula $X-P(R_2)(R_3)$, where X is a halogen, with chlorine being more preferred.

The amino moieties of R_2 and R_3 can be selected from various amines presently used for phosphoramidites in standard oligonucleotide synthesis. In preferred embodiments of the invention, R_2 and R_3 each have the Formula

-N(R₅)(R₆), where R₅ and R₆ are each independently alkyl having from one to four carbon atoms, or R₅ and R₆ taken together with the nitrogen atom to which they are attached form an aliphatic or aromatic five or six membered ring. It is generally preferred, but not required, that each R₅ and R₆ be the same.

In some particularly preferred embodiments of the present invention, R₅ and R₆ are alkyl, with isopropyl being preferred. Further examples of suitable amines useful as amino moieties of the phosphordiamidites of the invention are described in various United States patents, principally those to M. Caruthers and associates. These include United States patents 4,668,777; 4,458,066; 4,415,732; and 4,500,707; the disclosures of which are herein incorporated by reference in their entirety.

The constituent sugars and nucleosidic bases of the phosphoramidites produced by the methods of the present invention can be naturally occurring or non-naturally occurring. Non-naturally occurring sugars and nucleosidic bases are typically structurally distinguishable from, yet functionally interchangeable with, naturally occurring sugars (e.g. ribose and deoxyribose) and nucleosidic bases (e.g., adenine, guanine, cytosine, thymine and uracil). Thus, non-naturally occurring nucleobases and sugars include all such structures which mimic the structure and/or function of naturally occurring species, and which aid in the binding of an oligomer incorporating the nucleobase and/or sugar to a target, or which otherwise advantageously contribute to the properties of such an oligomer.

For example, representative nucleobases suitable for use in the methods of the invention include adenine, guanine, cytosine, uridine, and thymine, as well as other non-naturally occurring and natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halo uracil and

cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo uracil), 4-thiouracil, 8-halo, oxa, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine. Further naturally and non naturally occurring nucleobases include those disclosed in U.S. Patent No. 3,687,808 (Merigan, et al.), in chapter 15 by Sanghvi, in *Antisense Research and Application*, Ed. S. T. Crooke and B. Lebleu, CRC Press, 1993, in Englisch et al., 10 *Angewandte Chemie*, International Edition, 1991, 30, 613-722 (see especially pages 622 and 623, and in the *Concise Encyclopedia of Polymer Science and Engineering*, J.I. Kroschwitz Ed., John Wiley & Sons, 1990, pages 858-859, Cook, P.D., *Anti-Cancer Drug Design*, 1991, 6, 585-607, the 15 disclosures of which are herein incorporated by reference in their entirety. The terms "nucleosidic base" and "nucleobase" are further intended to include heterocyclic compounds that can serve as nucleosidic bases, including certain "universal bases" that are not nucleosidic bases in 20 the most classical sense, but function similarly to nucleosidic bases. One representative example of such a universal base is 3-nitropyrrole.

The nucleobases employed in the methods of the present invention can bear protecting groups. Typically, 25 such nucleobase protecting groups are base labile, and serve to protect the exocyclic amino groups of the heterocyclic nucleobases. In some preferred embodiments, this type of protection is achieved by acylation with an acylating reagent such as, for example, benzoylchloride or isobutyryl- 30 chloride. These protecting groups are stable to the reaction conditions of the methods of the present invention, as well as the conditions of oligonucleotide synthesis. Typically, such protecting groups are cleaved at approximately equal rates during treatment with base at the

end of oligonucleotide synthesis.

The present invention provides methods for the preparation of phosphoramidites having substituents at, for example, the 2'-position. Representative 2'-substituents (i.e., moieties represented by "Z" in the structures herein) include but are not limited to H, OH, F, or a group of formula $R_7-(R_8)_n$ wherein R_7 is C_3-C_{20} alkyl, C_4-C_{20} alkenyl, C_2-C_{20} alkynyl, C_1-C_{20} alkoxy, C_2-C_{20} alkenyloxy, or C_2-C_{20} alkynyloxy; and R_8 is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides.

Preferred 2' modifications include 2'-methoxyethoxy ($2'-O-CH_2CH_2OCH_3$, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylamino oxyethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE, as described in co-owned United States patent application Serial Number 09/016,520, filed on January 30, 1998, the contents of which are herein incorporated by reference.

Other preferred 2' modifications include 2'-methoxy ($2'-O-CH_3$), 2'-aminopropoxy ($2'-OCH_2CH_2CH_2NH_2$) and 2'-fluoro ($2'-F$). Similar modifications may also be made at other positions on the sugar group, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5'

terminal nucleotide. The nucleosides of the oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Representative United States patents that teach the preparation of such modified sugars structures include, but are not limited to, U.S. Patents 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the present application, each of which is herein incorporated by reference, together with allowed United States patent application 08/468,037, filed on June 5, 1995, which is commonly owned with the present application and is herein incorporated by reference.

In some preferred embodiments, the methods of the invention are employed to prepare phosphoramidites having 2'-O substituents that are polyethers of the formula (O-alkyl)_m, where m is 1 to about 10. Preferred among these polyethers are linear and cyclic polyethylene glycols (PEGs), and (PEG)-containing groups, such as crown ethers and those which are disclosed by Ouchi, et al., *Drug Design and Discovery* 1992, 9, 93, Ravasio, et al., *J. Org. Chem.* 1991, 56, 4329, and Delgado et. al., *Critical Reviews in Therapeutic Drug Carrier Systems* 1992, 9, 249. Further sugar modifications are disclosed in Cook, P.D., *supra*. Fluoro, O-alkyl, O-alkylamino, O-alkyl imidazole, O-alkylaminoalkyl, and alkyl amino substitution is described in United States Patent Application serial number 08/398,901, filed March 6, 1995, entitled Oligomeric Compounds having Pyrimidine Nucleotide(s) with 2' and 5' Substitutions, the disclosure of which is hereby incorporated by reference.

Sugars having O-substitutions on the ribosyl ring are also amenable to the present invention. Representative substitutions for ring O include S, CH₂, CHF, and CF₂, see,

e.g., Secrist, et al., *Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleosides, Nucleotides and their Biological Applications*, Park City, Utah, Sept. 16-20, 1992.

- 5 The phosphorus protecting group R_4 , is a group that is useful for protecting phosphorus containing internucleoside linkages during, for example, solid state oligonucleotide synthetic regimes. Examples of such phosphorus protecting groups include β -cyanoethyl, 10 diphenylsilylethyl, δ -cyanobutenyl, cyano *p*-xylyl (CPX), *N*-methyl-*N*-trifluoroacetyl ethyl (META), acetoxo phenoxy ethyl (APE) and butene-4-yl groups. See for example U.S. Patents Nos. 4,725,677 and Re. 34,069 (β -cyanoethyl); Beaucage, S.L. and Iyer, R.P., *Tetrahedron*, **49** No. 10, pp. 1925-1963 15 (1993); Beaucage, S.L. and Iyer, R.P., *Tetrahedron*, **49** No. 46, pp. 10441-10488 (1993); Beaucage, S.L. and Iyer, R.P., *Tetrahedron*, **48** No. 12, pp. 2223-2311 (1992). See also U.S. Patents Nos.

20 In some preferred embodiments of the methods of the present invention, mononucleoside phosphoramidite compounds are prepared from nucleosides having a free 3'-hydroxyl. Such mononucleoside phosphoramidites are useful for example, in the solid state synthesis of oligonucleotides. Additionally, the methods of the present 25 invention can be used to prepare dimeric, trimeric, or higher order nucleotide 3'-phosphoramidite compounds, from suitably protected oligomeric compounds having a free terminal 3'-hydroxyl group. Such phosphoramidites are useful, for example, in synthetic regimes wherein an 30 oligomeric "block" is added to a growing chain in a single coupling step. Thus, in preferred embodiments, the compounds of Formula II include both mononucleosides (i.e., q is 0) and oligomers that have a free 3'-hydroxyl (i.e., q is greater than 1). Preferably, q is from 0 to about 100;

more preferably from 0 to about 25, even more preferably from about 0 to about 10, with 0 to about 5 being more preferred. In especially preferred embodiments, q is 0, 1 or 2, with 0 being most preferred.

5 The methods of the present invention can be used to prepare oligomeric 3'-phosphoramidites having a wide variety of internucleotide linkages, represented by "M" in the structures provided herein. Examples of internucleoside linkages which can be present in the compounds of Formula I,
10 II and IV include phosphodiester, phosphorothioate, phosphorodithioate, and phosphonate linkages. Further representative internucleotide linkages include amide or substituted amide linkages, such as those described in Waldner et al., *Synlett.* 1, 57-61 (1994), De Mesmaeker et
15 al., *Synlett.* 10, 733-736 (1993), Lebreton et al., *Synlett.* 2, 137-140 (1994), De Mesmaeker et al., *Bioorg. Medic. Chem. Lett.* 4, 395-398 (1994), De Mesmaeker et al., *Bioorg. Medic. Chem. Lett.* 4, 873-878 (1994), Lebreton et al., *Tet. Letters* 34, 6383-6386 (1993), Lebreton et al., *Tet. Letters* 35,
20 5225-5228 (1994), Waldner et al., *Bioorg. Medic. Chem. Lett.* 4, 405-408 (1994), and linkages described in U.S. Patent No. 5,489,677, U.S. Ser. No. 08/317,289, filed October 3, 1994, U.S. Ser. No. 08/395,168, filed February 27, 1995.

As used herein, the term "alkyl" includes but is
25 not limited to straight chain, branch chain, and alicyclic hydrocarbon groups. Alkyl groups of the present invention may be substituted. Representative alkyl substituents are disclosed in United States Patent No. 5,212,295, at column 12, lines 41-50.

30 The term "alkenyl" includes but is not limited to straight chain, branch chain, and alicyclic hydrocarbon groups that have at least one carbon-carbon double bond.

 The term "alkynyl" includes but is not limited to straight chain, branch chain, and alicyclic hydrocarbon

groups that have at least one carbon-carbon triple bond.

The terms "alkoxy" "alkenyloxy" and "alkynyloxy" denote groups of the formula A-O- where A is, respectively, an alkyl group, and alkenyl group, or an alkynyl group.

5 As used herein, the term "aralkyl" denotes alkyl groups which bear aryl groups, for example, benzyl groups. The term "alkaryl" denotes aryl groups which bear alkyl groups, for example, methylphenyl groups. "Aryl" groups are aromatic cyclic compounds including but not limited to
10 phenyl, naphthyl, anthracyl, phenanthryl, and pyrenyl groups.

The term "heterocycle" denotes an aliphatic or aromatic ring or ring system having at least one heteroatom therein. The term heteroatom means a non-carbon atom,
15 such as O, N or S.

As used herein, the term O-alkylamino denotes a group of formula O-alkyl-NH₂. The term O-alkylalkoxy denotes a group of formula -O-alkyl-O-alkyl. The term O-alkylaminoalkyl denotes an O-alkylamino group wherein the
20 amino moiety bears one or more additional alkyl groups. The

As used herein, the term "heterocycloalkyl" denotes an alkyl ring system having one or more heteroatoms (i.e., non-carbon atoms). Preferred heterocycloalkyl groups include, for example, morpholino groups. As used herein,
25 the term "heterocycloalkenyl" denotes a ring system having one or more double bonds, and one or more heteroatoms. Preferred heterocycloalkenyl groups include, for example, pyrrolidino groups.

Halogens include F, Cl, Br and I.

30 Polyamines are groups having the general formula -[A-NH]_v-H; -[NH-A]_v; -[A-NH-A]_v; or -[NH-A-NH]_t-H where A is alkyl, alkenyl or alkynyl, v is greater than one, and t is one or greater.

As used herein, the term "nucleoside" denotes a
35 pentofuranosyl sugar which is bound to a nucleosidic base (i.e., a nitrogenous heterocyclic base or "nucleobase").

As used herein, the term "oligonucleotide" denotes a plurality of pentofuranose units which bear nucleobases, linked by an internucleotide linkage. Included within the definition of "oligonucleotide" are naturally occurring
5 oligonucleotides such as ribose and deoxyribose phosphodiester, and their analogs such as phosphorothioates, phosphorodithioates, and phosphonates.

As used herein, the term "intercalator" means a moiety that is known to intercalate into double stranded
10 DNA. Typically intercalators are planar molecules, for example acridine.

As used herein, the term "reporter molecule" means a molecule that is detectable. Included within the definition of "reporter molecule" are radiolabels (e.g.,
15 compounds containing an enriched amount of a radioactive atom such as ^{14}C , ^3H , or ^{31}P), chromophores, fluorophores, and enzymes that are detectable via their enzymatic function.

In some preferred embodiments of the invention amino groups are appended to alkyl or other groups, such as,
20 for example, 2'-alkoxy groups (e.g., where R_7 is alkoxy and R_8 is NH-alkyl). Such amino groups are also commonly present in naturally occurring and non-naturally occurring nucleobases. It is generally preferred that these amino groups be in protected form during the synthesis of
25 oligomeric compounds of the invention. Representative amino protecting groups suitable for these purposes are discussed in Greene and Wuts, *Protective Groups in Organic Synthesis*, Chapter 7, 2d ed, John Wiley & Sons, New York, 1991. Generally, as used herein, the term "protected" when used in
30 connection with a molecular moiety such as "nucleobase" indicates that the molecular moiety contains one or more functionalities protected by protecting groups.

Additional advantages and novel features of this invention will become apparent to those skilled in the art
35 upon examination of the examples thereof provided below, which should not be construed as limiting the appended

claims.

EXAMPLES

Example 1

5'-O-Dimethoxytritylthymidine-3'-O-(4-cyanomethylbenzyl) -

5 N,N-diisopropyl phosphoramidite

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum was assembled under an atmosphere of argon. All the glassware was dried at 120°C for 1 hour. 5'-O-DMT thymidine (3.7 mmole), pyridine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture was stirred for 20 minutes and a solution of 4-cyanomethylbenzyl alcohol (4.28 mmole) in acetonitrile (5 ml) dried over 4 Å molecular sieves was added. The reaction mixture was stirred at room temperature for 1 hour. All the volatiles were removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography afforded the phosphoramidite as a colorless solid.

Example 2

5'-O-Dimethoxytrityl-thymidine-3'-O-(2-cyanoethyl) -N,N-

25 diisopropyl phosphoramidite

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum was assembled under an atmosphere of argon. All the glassware was dried at 120°C for 1 hour. 5'-O-DMT thymidine (3.7 mmole), pyridine (5.55 mmol) and acetonitrile (95 ml) were added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room

temperature. The reaction mixture was stirred, and then a solution of 3-hydroxypropionitrile (4.28 mmol) in acetonitrile (5 ml) dried over 4 A molecular sieves was added. The reaction mixture was stirred at room temperature
5 for 12 hour. All the volatiles were removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography afforded the phosphoramidite as a
10 colorless solid.

Example 3

5'-O-Dimethoxytrityl-thymidine-3'-O-(2-diphenylmethylsilylethyl)-N,N-diisopropyl phosphoramidite

A 250 ml three-necked flask equipped with a
15 magnetic stirrer, a gas inlet for argon, and a septum is assembled under an atmosphere of argon. All the glassware is dried at 120°C for 1 hour. 5'-O-DMT thymidine (3.7 mmole), pyridine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by
20 bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture is stirred for 20 minutes and a solution of 2-diphenylmethylsilyl ethyl alcohol (4.28 mmol) in acetonitrile (5 ml) dried over 4 A molecular sieves is added. The reaction mixture is stirred at room
25 temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography affords the
30 phosphoramidite as a colorless solid.

Example 4

5'-O-Dimethoxytritylthymidine-3'-O-(N-methyl-N-trifluoroacetylaminoethyl)-N,N-diisopropyl phosphoramidite

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum is assembled under an atmosphere of argon. All the glassware is dried at 120°C for 1 hour. 5'-O-DMT thymidine (3.7 mmole), pyridine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture is stirred for 20 minutes and a solution of N-methyl-N-trifluoroacetyl ethyl alcohol (4.28 mmol) in acetonitrile (5 ml) dried over 4 Å molecular sieves is added. The reaction mixture is stirred at room temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography affords the phosphoramidite as a colorless solid.

Example 5

N2-Isobutyryl-5'-O-Dimethoxytrityl-2'-deoxyguanosine-3'-O-(4-cyanomethylbenzyl)-N,N-diisopropylphosphoramidite

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum was assembled under an atmosphere of argon. All the glassware was dried at 120°C for 1 hour. 5'-O-DMT-2'-deoxyguanosine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) were added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture was stirred for 20 minutes and a solution of 4-cyanomethylbenzyl alcohol (4.28 mmole) in acetonitrile (5 ml) dried over 4 Å molecular sieves was added. The reaction mixture was stirred at room temperature overnight. All the volatiles were removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and

dried. Concentration of the dried extract and purification using flash chromatography afforded the phosphoramidite as a colorless solid.

Example 6

5 **N2-Isobutyryl-5'-O-dimethoxytrityl-2'-deoxyguanosine-3'-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite**

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum was assembled under an atmosphere of argon. All the glassware
10 was dried at 120°C for 1 hour. N2-Isobutyryl-5'-O-DMT-2'-deoxyguanosine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) were added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture was stirred, and then a
15 solution of 3-hydroxypropionitrile (4.28 mmol) in acetonitrile (5 ml) dried over 4 Å molecular sieves was added. The reaction mixture was stirred at room temperature for 12 hour. All the volatiles were removed under reduced pressure and the residue extracted into an organic solvent,
20 washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography afforded the phosphoramidite as a colorless solid.

Example 7

25 **N2-Isobutyryl-5'-O-dimethoxytrityl-2'-deoxyguanosine-3'-O-(2-diphenylmethylsilylethyl)-N,N-diisopropylphosphoramidite**

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum is assembled under an atmosphere of argon. All the glassware
30 is dried at 120°C for 1 hour. N2-Isobutyryl-5'-O-DMT-2'-deoxyguanosine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room

temperature. The reaction mixture is stirred for 20 minutes and a solution of 2-diphenylmethylsilyl ethyl alcohol (4.28 mmol) in acetonitrile (5 ml) dried over 4 A molecular sieves is added. The reaction mixture is stirred at room
5 temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and
10 purification using flash chromatography affords the phosphoramidite as a colorless solid.

Example 8

N2-Isobutyryl-5'-O-dimethoxytrityl-2'-deoxyguanosine-3'-O-(N-methyl-N-trifluoroacetyl-aminoethyl)-N,N-diisopropylphosphoramidite

15 A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum is assembled under an atmosphere of argon. All the glassware is dried at 120°C for 1 hour. N2-Isobutyryl-5'-O-DMT-2'-
20 deoxyguanosine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture is stirred for 20 minutes and a solution of N-methyl-N-trifluoroacetyl-ethyl alcohol
25 (4.28 mmol) in acetonitrile (5 ml) dried over 4 A molecular sieves is added. The reaction mixture is stirred at room temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate
30 solution and dried. Concentration of the dried extract and purification using flash chromatography affords the phosphoramidite as a colorless solid.

Example 9

N4-Benzoyl-5'-O-dimethoxytrityl-2'-deoxycytidine-3'-O-(4-

cyanomethylbenzyl)-N,N-diisopropylphosphoramidite

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum was assembled under an atmosphere of argon. All the glassware was dried at 120°C for 1 hour. N4-Benzoyl-5'-O-DMT-2'-deoxycytidine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) were added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture was stirred for 20 minutes and a solution of 4-cyanomethylbenzyl alcohol (4.28 mmole) in acetonitrile (5 ml) dried over 4 Å molecular sieves was added. The reaction mixture was stirred at room temperature overnight. All the volatiles were removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography afforded the phosphoramidite as a colorless solid.

Example 10**20 N4-Benzoyl-5'-O-dimethoxytrityl-2'-deoxycytidine-3'-O-(2-cyanoethyl)-N,N-diisopropyl phosphoramidite**

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum was assembled under an atmosphere of argon. All the glassware was dried at 120°C for 1 hour. N4-Benzoyl-5'-O-DMT-2'-deoxycytidine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) were added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture was stirred, and then a solution of 3-hydroxypropionitrile (4.28 mmol) in acetonitrile (5 ml) dried over 4 Å molecular sieves was added. The reaction mixture was stirred at room temperature for 12 hour. All the volatiles were removed under reduced pressure and the residue extracted into an organic solvent,

washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography afforded the phosphoramidite as a colorless solid.

5 **Example 11**

N4-Benzoyl-5'-O-dimethoxytrityl-2'-deoxycytidine-3'-O-(2-diphenylmethylsilylethyl)-N,N-diisopropylphosphoramidite

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum is assembled under an atmosphere of argon. All the glassware is dried at 120°C for 1 hour. N4-Benzoyl-5'-O-DMT-2'-deoxycytidine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture is stirred for 20 minutes and a solution of 2-diphenylmethylsilyl ethyl alcohol (4.28 mmol) in acetonitrile (5 ml) dried over 4 Å molecular sieves is added. The reaction mixture is stirred at room temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography affords the phosphoramidite as a colorless solid.

25 **Example 12**

N4-Benzoyl-5'-O-dimethoxytrityl-2'-deoxycytidine-3'-O-(N-methyl-N-trifluoroacetyl aminoethyl)-N,N-diisopropylphosphoramidite

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum is assembled under an atmosphere of argon. All the glassware is dried at 120°C for 1 hour. N4-Benzoyl-5'-O-DMT-2'-

deoxycytidine (3.7 mmole), triethylamine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture is stirred for 20 minutes
5 and a solution of N-methyl-N-trifluoroacetyethyl alcohol (4.28 mmol) in acetonitrile (5 ml) dried over 4 Å molecular sieves is added. The reaction mixture is stirred at room temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an
10 organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography affords the phosphoramidite as a colorless solid.

Example 13

15 **N6-Benzoyl-5'-O-dimethoxytrityl-2'-deoxyadenosine-3'-O-(4-cyanomethylbenzyl)-N,N-diisopropyl phosphoramidite**

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum was assembled under an atmosphere of argon. All the glassware
20 was dried at 120°C for 1 hour. N6-Benzoyl-5'-O-DMT-2'-deoxyadenosine (3.7 mmole), pyridine (5.55 mmol) and acetonitrile (95 ml) were added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture was stirred for 20
25 minutes and a solution of 4-cyanomethylbenzyl alcohol (4.28 mmole) in acetonitrile (5 ml) dried over 4 Å molecular sieves was added. The reaction mixture was stirred at room temperature for 12 hour. All the volatiles were removed under reduced pressure and the residue extracted into an
30 organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and purification using flash chromatography afforded the phosphoramidite as a colorless solid.

Example 14**N6-Benzoyl-5'-O-dimethoxytrityl-2'-deoxyadenosine-3'-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite**

A 250 ml three-necked flask equipped with a
5 magnetic stirrer, a gas inlet for argon, and a septum was
assembled under an atmosphere of argon. All the glassware
was dried at 120°C for 1 hour. N6-Benzoyl-5'-O-DMT-2'-
deoxyadenosine (3.7 mmole), pyridine (5.55 mmol) and
acetonitrile (95 ml) were added to the flask followed by
10 bis(diisopropylamino)chlorophosphine (4.44 mole) at room
temperature. The reaction mixture was stirred, and then a
solution of 3-hydroxypropionitrile (4.28 mmol) in
acetonitrile (5 ml) dried over 4 Å molecular sieves was
added. The reaction mixture was stirred at room temperature
15 for 12 hour. All the volatiles were removed under reduced
pressure and the residue extracted into an organic solvent,
washed with aqueous sodium bicarbonate solution and dried.
Concentration of the dried extract and purification using
flash chromatography afforded the phosphoramidite as a
20 colorless solid.

Example 15**N6-Benzoyl-5'-O-dimethoxytrityl-2'-deoxyadenosine-3'-O-(2-diphenylmethylsilylethyl)-N,N-diisopropylphosphoramidite**

A 250 ml three-necked flask equipped with a
25 magnetic stirrer, a gas inlet for argon, and a septum is
assembled under an atmosphere of argon. All the glassware
is dried at 120°C for 1 hour. N6-Benzoyl-5'-O-DMT-2'-
deoxyadenosine (3.7 mmole), pyridine (5.55 mmol) and
acetonitrile (95 ml) are added to the flask followed by
30 bis(diisopropylamino)chlorophosphine (4.44 mole) at room
temperature. The reaction mixture is stirred for 20 minutes
and a solution of 2-diphenylmethylsilylethyl alcohol (4.28
mmol) in acetonitrile (5 ml) dried over 4 Å molecular sieves
is added. The reaction mixture is stirred at room

temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate solution and dried. Concentration of the dried extract and
5 purification using flash chromatography affords the phosphoramidite as a colorless solid.

Example 16

N6-Benzoyl-5'-O-dimethoxytrityl-2'-deoxyadenosine-3'-O-(N-methyl-N-trifluoroacetyl-aminoethyl)-N,N-
10 **diisopropylphosphoramidite**

A 250 ml three-necked flask equipped with a magnetic stirrer, a gas inlet for argon, and a septum is assembled under an atmosphere of argon. All the glassware is dried at 120°C for 1 hour. N6-Benzoyl-5'-O-DMT-2'-
15 deoxyadenosine (3.7 mmole), pyridine (5.55 mmol) and acetonitrile (95 ml) are added to the flask followed by bis(diisopropylamino)chlorophosphine (4.44 mole) at room temperature. The reaction mixture is stirred for 20 minutes and a solution of N-methyl-N-trifluoroacetyl-ethyl alcohol
20 (4.28 mmol) in acetonitrile (5 ml) dried over 4 Å molecular sieves is added. The reaction mixture is stirred at room temperature for 12 hours. All the volatiles are removed under reduced pressure and the residue extracted into an organic solvent, washed with aqueous sodium bicarbonate
25 solution and dried. Concentration of the dried extract and purification using flash chromatography affords the phosphoramidite as a colorless solid.


It is intended that each of the patents, applications, printed publications, and other published
30 documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes

and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

What is claimed is:

1. A method for the preparation of a phosphoramidite of Formula:



5

wherein:

R_1 is a hydroxyl protecting group;

B is a nucleobase;

M is an internucleotide linkage;

10

q is 0 to about 100;

Z is H, OH, F, or a group of formula $R_7-(R_8)_n$;

R_7 is C_3-C_{20} alkyl, C_4-C_{20} alkenyl, C_2-C_{20} alkynyl, C_1-C_{20} alkoxy, C_2-C_{20} alkenyloxy, or C_2-C_{20} alkynyloxy;

15 R_8 is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, 20 disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the

pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

n is from 0 to about 10;


5 R_3 is a group of formula $-N(R_5)(R_6)$;

R_5 and R_6 are independently alkyl having from one to four carbon atoms, or R_5 and R_6 taken together with the nitrogen atom to which they are attached form an aliphatic or aromatic five or six membered ring;


10 R_4 is a phosphorus protecting group;

comprising:

providing a compound Formula:




15 and reacting the compound with a diaminohalophosphine of Formula:



wherein X is halogen; and R_2 is a group of formula $-N(R_5)(R_6)$;

20 to produce a phosphordiamidite of Formula:



and

contacting the nucleoside phosphordiamidite with a reagent of Formula R₄-OH to produce the nucleoside phosphoramidite.

- 5 2. The method of claim 1 wherein q is 0.
3. The method of claim 1 wherein R₁ is trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl (MOX).
- 10 4. The method of claim 1 wherein R₁ is trityl, monomethoxy trityl or dimethoxytrityl.
5. The method of claim 1 wherein each R₅ and R₆ are the same.
6. The method of claim 1 wherein R₅ and R₆ are
15 each alkyl.
7. The method of claim 1 wherein each R₅ and R₆

is isopropyl.

8. The method of claim 1 wherein Z is H, OH, F, or a group of formula $R_7-(R_8)_n$ where R_7 is C_1-C_{20} alkoxy, C_2-C_{20} alkenyloxy, or C_2-C_{20} alkynyloxy; R_8 is hydrogen; and n is 1.

5 9. The method of claim 1 wherein R_4 is β -cyanoethyl, diphenylsilylethyl, δ -cyanobutenyl, cyano *p*-xylyl (CPX), N-methyl-N-trifluoroacetyl ethyl (META), acetoxo phenoxy ethyl, or butene-4-yl.

10 10. The method of claim 1 wherein R_4 is β -cyanoethyl, diphenylsilylethyl, δ -cyanobutenyl, acetoxo phenoxy ethyl or cyano *p*-xylyl.

11. The method of claim 1 wherein X is chlorine.

15 12. The method of claim 8 wherein R_4 is β -cyanoethyl, diphenylsilylethyl, δ -cyanobutenyl, acetoxo phenoxy ethyl or cyano *p*-xylyl; and each R_5 and R_6 is alkyl.

13. The method of claim 12 wherein each R_5 and R_6 is isopropyl.

20 14. The method of claim 1 wherein the nucleoside is reacted with the diaminoalophosphine in acetonitrile or dichloromethane solvent.

15. The method of claim 14 wherein the nucleoside is reacted with the diaminoalophosphine in acetonitrile solvent.

25 16. The method of claim 14 wherein the nucleoside is reacted with the diaminoalophosphine in the presence of a base.

17. The method of claim 16 wherein said base is Hunig's base, pyridine, triethylamine or a mixture of pyridine and triethylamine.

5 18. The method of claim 1 wherein the nucleoside phosphordiamidite is contacted with the reagent of formula R_4 -OH in the presence of triethylamine, pyridine or a mixture thereof.

10 19. A method for the preparation of a mononucleoside phosphoramidite or oligonucleotide phosphoramidite comprising the steps of:

 reacting a mononucleoside or an oligonucleotide having a free 3'-hydroxyl with a diaminohalophosphine; and
 contacting the product of the reaction with a
15 reagent of formula R_4 -OH, where R_4 is a phosphorus protecting group, under conditions of time and temperature sufficient to form the mononucleoside phosphoramidite or oligonucleotide phosphoramidite.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13121

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/00, 21/04

US CL : 536/25.3, 25.34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/25.3, 25.34

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAPLUS, CAOLD, BEILSTEIN, MEDLINE, BIOSIS: BISALKYLAMINO, CHLOROPHOSPHINE, PHOSPHORAMIDES, PHOSPHORAMIDITES

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - Y - A	MARUGG et al. A New And Versatile Approach to the Preparation of Valuable Deoxynucleoside 3-Phosphite Intermediates Tetrahedron Letters. 1986, Vol. 27, No. 20, pages 2271-2274, see esp. the synthetic scheme for preparing compound IV on page 2272.	1-13, 15-18 ----- 14-15 ----- 19

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents.	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*g* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 AUGUST 1999

Date of mailing of the international search report

24 AUG 1999

Name and mailing address of the ISA US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No (703) 305-3230

Authorized officer

GARY L. KUNZ

Telephone No. (703) 308-1235